Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07135050
PHASE1/PHASE2

Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome

Sponsor: Mahzi Therapeutics

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if MZ-1866 is a safe and tolerable treatment for children and adults with Pitt Hopkins Syndrome. To evaluate the safety of MZ-1866, the following will be evaluated: * frequency and severity of adverse events * physical exam, laboratory results and electrocardiogram findings Participants will: * receive a single dose of MZ-1866 by intracerebroventricular injection * be seen by the study physician and site staff periodically to assess changes to their health status * be periodically evaluated using neurodevelopmental tools Caregivers will: * be interviewed periodically about the health status and development of the participant * keep diaries and complete periodic questionnaires regarding participant symptoms

Official title: Phase 1/2 First-in-Human Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome

Key Details

Gender

All

Age Range

2 Years - 25 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2025-12-19

Completion Date

2029-07

Last Updated

2026-02-23

Healthy Volunteers

No

Interventions

GENETIC

MZ-1866

AAV-9 gene therapy delivered by intracerebroventricular injection

Locations (3)

UCSF Benioff Children's Hospital Oakland

Oakland, California, United States

Children's Hospital Colorado

Aurora, Colorado, United States

Rush University Medical Center

Chicago, Illinois, United States